Anbio Biotechnology Class A Company Profile
NASDAQ: NNNNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Anbio Biotechnology at a glance
Anbio Biotechnology Class A (NASDAQ: NNNN) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Frankfurt am Main, Germany. Anbio Biotechnology is led by Mr. Michael Lau M.B.A., Ph.D. and employs about 27 people. The company's shares have traded publicly since 2025.
At a market capitalization of $202.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001982708, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Anbio Biotechnology do?
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Business description based on the company's public filings.
Company information
- Legal name
- Anbio Biotechnology Class A
- Ticker
- NASDAQ: NNNN
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Michael Lau M.B.A., Ph.D.
- Employees
- 27
- Headquarters
- Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, Germany
- Phone
- 49 698 7003 9170
- Website
- anbiobiotechnology.com
- IPO year
- 2025
- Market cap
- $202.78M
- SEC CIK
- 0001982708
Companies similar to Anbio Biotechnology
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMDXInsight Molecular Diagnostics Inc. | 3.28 | -5.20% | $107.34M | vs NNNN |
| ICCCImmuCell Corporation | 9.75 | +0.62% | $88.55M | vs NNNN |
| BMRABiomerica Inc. | 1.89 | -0.53% | $8.69M | vs NNNN |
| VNRXVolitionRX Limited | 0.2194 | -2.92% | $6.60M | vs NNNN |
| CDIOCardio Diagnostics Holdings Inc. | 1.86 | -5.58% | $5.50M | vs NNNN |
| QCLSQ/C Technologies Inc. | 0.6367 | +0.74% | $5.21M | vs NNNN |
| TRIBTrinity Biotech plc ADR | 6.04 | -10.91% | $4.91M | vs NNNN |
| MYGNMyriad Genetics Inc. | 4.20 | -1.87% | $401.73M | vs NNNN |